Search

  • Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • critical-appraisal
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • review-paper
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Immunohematology

 

Report | 01-December-2019

Directed blood donor program decreases donor exposure for children with sickle cell disease requiring chronic transfusion

In children with sickle cell disease (SCD), primary and secondary prevention of strokes require indefinite regular blood transfusion therapy. The risks associated with repeated transfusions include alloimmunization and increased donor exposure. The Charles Drew Program is a directed blood donor program designed to lower donor exposure, decreasing the associated complications of transfusion; however, no evidence exists demonstrating the magnitude of the benefit to the recipient. Further, the use

Dionna O. Roberts, Brittany Covert, Terianne Lindsey, Vincent Edwards, Lisa McLaughlin, John Theus, Ricardo J. Wray, Keri Jupka, David Baker, Mary Robbins, Michael R. DeBaun

Immunohematology, Volume 28 , ISSUE 1, 7–12

Report | 01-December-2019

Should blood donors be routinely screened for irregular antibodies?

components to avoid transfusion-related acute lung syndrome. Total blood donor population between 2007 and 2009 was 60,309 (55.4% male and 44.6% female). Cells I and II were used for alloantibody screening following the Autovue protocol. Positive samples were identified by red blood cell (RBC) panels (Panel A, Panel B, and Panel C, Ortho Clinical Diagnostics, Raritan, NJ). Alloantibody and CSAA frequency were established for both sexes. The database for RBC antigens estimated for the Colombian population

Michel Andrés García, Leonardo Bautista, Fernando Palomino

Immunohematology, Volume 28 , ISSUE 2, 60–66

Article | 10-April-2021

Group O blood donors in Iran: evaluation of isoagglutinin titers and immunoglobulin G subclasses

macroscopic agglutination (1+ reactivity). Since some of the blood donor samples showed high levels of isoagglutinins, even without previous RBC exposure, it became of interest to investigate alloantibody production and IgG subclasses. In this study, we compared levels of alloantibody and IgG subclasses within two groups of individuals (high-titers vs. non–high-titers). Thus, 22 plasma samples (11 samples with titers greater than 512 [high-titer group] and 11 samples with titers less than 128 [non–high

S. Arabi, M. Moghaddam, A.A. Pourfathollah, A. Aghaie, M. Mosaed

Immunohematology, Volume 37 , ISSUE 1, 5–12

Article | 06-December-2020

En(a-) phenotype in a Japanese blood donor

Yasuto Okubo, Taiko Seno, Hideo Yamaguchi, Yoshihisa Miyata, Carole A. Green, Geoffrey L. Daniels

Immunohematology, Volume 9 , ISSUE 4, 105–108

Review | 18-May-2020

A review of the ISBT rare blood donor program

Graeme Woodfield, Joyce Poole, Sandra Taddie Nance, Geoff Daniels

Immunohematology, Volume 20 , ISSUE 4, 244–248

Report | 01-December-2019

RHCE variant allele: RHCE*ce254G,733G

A novel RHCE allele was identified in a 53-year-old AfricanAmerican female blood donor with an Rh phenotype of D+ C– E– c+ e+ and a negative antibody screen. The donor’s cells typed e+ with all antisera tested. By gel-based genotyping and cDNA analysis, the two RHCE alleles in this donor were characterized. One allele was found to be the known allele RHCE*01.20.01 (RHCE*ce733G) and the second was novel: RHCE*01.06.02 (RHCE*ce254G,733G).

Jessica A. Keller, Trina Horn, Colleen Chiappa, Camilla Melland, Christine Vietz, Lilian Castilho, Margaret A. Keller

Immunohematology, Volume 30 , ISSUE 3, 121–122

Article | 13-April-2020

The Redelberger antigen: a family study, a family story

The Redelberger antigen (Rba) was first discovered in 1974 on the RBCs of a blood donor who was an employee of the Community Blood Center in Dayton, Ohio. The discovery was made as a result of the investigation of a reagent contamination problem. Two examples of the Rba antigen were subsequently identified in the United Kingdom,but no “new”examples have been identified in the United States or Europe. Anti-Rba is a commonly occurring antibody, often found in combination with other

Nancy A. Lang, Marilyn K. Moulds, Gail E. Coghlan

Immunohematology, Volume 22 , ISSUE 2, 48–51

Article | 30-November-2020

The incidence of V (Rh10) and Jsa (K6) in the contemporary African American blood donor

Peter C. Byrne, John H. Howard

Immunohematology, Volume 10 , ISSUE 4, 136–138

Article | 30-November-2020

First example of Rh:-32,-46 red cell phenotype

The red cells of a white male blood donor typed as Rh:-1, -2, -3, w4, w5, 6, -17, w19, -31, -32, -34, and -46. Although the donor has no history of transfusion, his serum contains an alloantibody that is weakly reactive with most red blood cells (RBCs) tested. Only Rhnull and D-- RBCs are nonreactive. Reactivity is enhanced with ficin- or papain-treated RBCs and is unaffected by AET or DTT treatment of the RBCs. Previously described Rh:-46 RBCs have been of deletion types D--, D•&bull

Jill Storry, Michael Gorman, Nancy I. Maddox, Ella Toy, Peter D. Issitt, Delores M. Mallory

Immunohematology, Volume 10 , ISSUE 4, 130–133

Article | 21-April-2020

Analysis of SERF in Thai blood donors

DAF. This study reports on PCR-RFLP analysis of the SERF allele with BstNI restriction endonuclease on more than one thousand Thai blood donor samples. One new donor homozygous (647T) and 21 donors heterozygous (647C/T) for the SERF allele were found. Among this cohort of random Thai blood donors,the SERF allele frequency was 1.1 percent. Thus, like other alleles in the Cromer blood group system, SERF is found in a certain ethnic group.

Poonsub Palacajornsuk, Kim Hue-Roye, Oytip Nathalang, Srisurang Tantimavanich, Sasitorn Bejrachandra, Marion Reid

Immunohematology, Volume 21 , ISSUE 2, 66–69

Letter to Editor | 16-October-2019

Letter to the Editor: Clinically significant naturally occurring anti-N and anti-S in a blood donor: a rare finding

Sheetal Malhotra, Gita Negi, Aseem Kumar Tiwari

Immunohematology, Volume 34 , ISSUE 2, 66–68

Article | 16-October-2019

Clinical and laboratory profile of anti-M

et al.5 reported the following prevalence rates in a northern Indian blood donor population: 34.6 percent M+N–, 54.1 percent M+N+, and 11.3 percent M–N+. Because the M antigen is destroyed by routinely available proteolytic enzymes, anti-M does not react with enzyme-treated red blood cells (RBCs).6 Anti-M is generally active below 37°C, with optimum activity at 4°C.6 Hence, these antibodies are generally ignored in transfusion practice, although they can interfere in ABO plasma grouping and cause

D. Basu, S. Basu, M. Reddy, K. Gupta, M. Chandy

Immunohematology, Volume 33 , ISSUE 4, 165–169

Article | 18-October-2020

Human anti-Dia monoclonal antibodies for mass screening

The use of monoclonal antibodies (mabs) to blood group antigens is constantly increasing for routine typing. Two heterohybridoma cell lines, HMR15 and HMR22, were established by Epstein-Barr virus transformation of peripheral blood lymphocytes from a blood donor with anti-Dia. HMR15 mab directly agglutinated Di(a+) red cells, and HMR22 mab agglutinated Di(a+) red cells exclusively by the indirect antiglobulin test. Reactivities of both HMR15 and HMR22 mabs were specific for Dia and had good

Toru Miyazaki, Shinichiro Sato, Toshiaki Kato, Hisami Ikeda

Immunohematology, Volume 16 , ISSUE 2, 78–81

Article | 03-November-2020

K phenotyping using a PK-7200 automated analyzer

K (Kell) is one of the most immunogenic of the red blood cell (RBC) antigens. In order to select K− RBC units, we developed K phenotyping on the Olympus PK-7200 equipment to save labor, time, and costs. The Olympus PK-7200 is fully automated equipment used primarily for blood typing and syphilis screening. We tested 3,587 blood donor samples in EDTA using a commercial anti-K serum diluted in HP Hemagen Power SolutionR(1:40). The equipment was set to prepare a 1.7% RBC suspension in

Marcia C. Zago-Novaretti, Silvana P. Navarro, Pedro E. Dorlhiac-Llacer, Dalton A.F. Chamone

Immunohematology, Volume 14 , ISSUE 1, 22–25

Article | 01-April-2020

Serologic and molecular characterization of the B(A) blood group in the Chinese population

resolve blood donor typing problems caused by B(A) alleles,a serologic and molecular study of nine unrelated Chinese individuals and three families carrying B(A) alleles was conducted. Allele B(A)02 with a 700C>G mutation,allele B(A)04 with a single 640A>G substitution, and allele B(A)05 with a 641T>C mutation were detected in multigenerational families and unrelated blood donors. Neither the B(A)01 nor B(A)03 alleles with 703A>G substitutions were observed in this study. In addition, a

Zhong-Hui Guo, Dong Xiang, Zi-Yan Zhu, Xi Liu, He-Ping Chen, Jian-Lian Wang, Da-Zhuang Liu, Tong-Mao Zhao

Immunohematology, Volume 23 , ISSUE 2, 69–74

Article | 10-November-2020

A new form of polyagglutination related to Cad

Four phenotypes of Cad (Cad 1–4) have been characterized by a continuum of polyagglutinability and reactivity with lectins, with the strongest Cad+ red blood cells (RBCs) being polyagglutinable because of the presence of anti-Cad (anti-Sda) in most normal sera. Over a period of 7 years, a French male blood donor’s RBCs demonstrated polyagglutinability with 50 percent to 70 percent of normal adult sera. The reactivity was characteristic of anti-Sda (refractile agglutination at 4°

Regina M. Leger, Elfreda J. Lines, Keith Cunningham, George Garratty

Immunohematology, Volume 12 , ISSUE 2, 69–71

Article | 15-April-2020

Chimerism and mosaicism are important causes of ABO phenotype and genotype discrepancies

Discrepancies between blood group genotype and RBC phenotype are important to recognize when implementing DNA-based blood grouping techniques. This report describes two such cases involving the ABO blood group in the Korean population. Propositus #1 was a 22-year-old healthy man undergoing pretransfusion testing for minor surgery. Propositus #2 was a 23year-old male blood donor. RBCs from both propositi were determined to be group AB and demonstrated unusual agglutination patterns on forward

Duck Cho, Jin Sol Lee, Mark Harris Yazer, Jong Won Song, Myung Geun Shin, Jong Hee Shin, Soon Pal Suh, Mee Jeong Jeon, Ji Young Kim, Jong Tae Park, Dong Wook Ryang

Immunohematology, Volume 22 , ISSUE 4, 183–187

Report | 12-March-2020

Application of real-time PCR and melting curve analysis in rapid Diego blood group genotyping

blood donor was found to be homozygous for DI*01 in this study. The calculated DI*01 and DI*02 allele frequencies were 0.0181 (95% CI, 0.0173–0.0189) and 0.9819 (95% CI, 0.9791–0.9847), respectively, showing a good fit for the Hardy-Weinberg equilibrium. There was full concordance among Diego phenotype results and Diego genotype results by PCR-SSP and real-time PCR. DI*01 and DI*02 allele determination with SYBR Green I and thermal cycler technology are useful methods for Diego

Marcia C. Zago Novaretti, Azulamara da Silva Ruiz, Pedro Enrique Dorlhiac-Llacer, Dalton Alencar Fisher Chamone

Immunohematology, Volume 26 , ISSUE 2, 66–70

Report | 20-March-2020

Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospitalbased donor center

transfusion was $20,345. In contrast, the current revenue generated by the collection of 60 therapeutic phlebotomies was only $6,000. In 2008, using eligible HH individuals as allogeneic blood donors would have resulted in an increase in revenue of $14,345 for our blood center. This study demonstrates that even at a medium-size, hospital-based donor center, obtaining a variance from the FDA to establish an HH blood donor program is a cost-effective endeavor, which does not compromise donor or patient

Dee M. Gribble, DJ Chaffin, Barbara J. Bryant

Immunohematology, Volume 25 , ISSUE 4, 170–173

Report | 25-March-2020

Molecular analyses of GYPB in African Brazilians

The molecular background of variant forms of GYPB is not well studied in Brazilians of African descent.  The present study was carried out to determine the molecular bases of the S–s– phenotype and the frequency of GYPB*S silent gene for the S–s+ phenotype in a blood donor population of African Brazilians.  In this study, 165 blood samples from African Brazilians (Northeastern Brazil) who phenotyped as S–s– (n = 17) and S–s+ (n = 148) by

Ricardo Omoto, Marion E. Reid, Lilian Castilho

Immunohematology, Volume 24 , ISSUE 4, 148–153

No Record Found..
Page Actions